Article Details

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies ... - BioBuzz

Retrieved on: 2022-09-08 21:21:08

Tags for this article:

Click the tags to see associated articles and topics

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies ... - BioBuzz. View article details on hiswai:

Excerpt

The Selexis-generated cell lines will be used to manufacture HLA IgG4 fusion proteins and T cell co-stimulatory monoclonal antibodies that will be ...

Article found on: biobuzz.io

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up